Investors should be gearing up for some movement in the biotech space, says iA Capital Markets analy... Read More
iA Capital Markets analyst Chelsea Stellick likes the progress being made by clinical-stage biopharm... Read More
Paradigm Capital delivered a healthcare sector update on Wednesday on drug developer NervGen Pharma ... Read More
Even with a shake-up at the helm, it’s still full steam ahead for Canadian biopharmaceutical compa... Read More
The Healthcare space has taken it on the chin this year, as stocks across the board are down by well... Read More
The stock just got a big boost from new clinical results, and that bodes well for fans of NervGen Ph... Read More
It’s been an uncomfortable stretch for fans of Healthcare stocks, with names across the board losi... Read More
Advances in clinical trials should move the needle big time on biopharm company NervGen Pharma (Ner... Read More
Paradigm Capital analyst Scott McAuley is staying bullish on NervGen Pharma (NervGen Pharma Stock Q... Read More
Chelsea Stellick of iA Capital Markets continues to have a positive outlook on NervGen Pharma (NervG... Read More
It seems fair to say that biotech hasn’t been the hottest of fields for much of this year. Money c... Read More
Chelsea Stellick of iA Capital Markets is staying bullish on biopharm company NervGen Pharma (NervG... Read More
Paradigm Capital analyst Scott McAuley believes NervGen Pharma (NervGen Pharma Stock Quote, Chart, N... Read More
Industrial Alliance Securities analyst Chelsea Stellick has launched coverage of NervGen Pharma (Ner... Read More
Share
Tweet
pin
Share